Page last updated: 2024-12-09

pedilstatin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pedilstatin: from a republic of maldives Pedilanthus sp.; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pedilstatin : A phorbol ester that is 4-deoxyphorbol in which the hydroxy groups at positions 12 and 13 have been replaced by octa-2,4-dienoyloxy and acetyloxy groups respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID643665
CHEMBL ID519593
CHEBI ID743
MeSH IDM0444649

Synonyms (13)

Synonym
(1ar,1bs,4ar,7ar,7br,8r,9r,9as)-9a-acetoxy-7b-hydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-1h-cyclopropa[3,4]benzo[1,2-e]azulen-9-yl (2z,4e)-octa-2,4-dienoate
CHEBI:743 ,
4-deoxy-4alpha-phorbol 13-acetate 12-(2z,4e)-octa-2,4-dienoate
13-o-acetyl-12-o-(z,e)-2,4-octadienoyl-4-desoxyphorbol
octa-2,4-dienoic acid 9a-acetoxy-7b-hydroxy-3-hydroxymethyl-1,1,6,8-tetramethyl-5-oxo-1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-1h-cyclopropa[3,4]benzo[1,2-e]azulen-9-yl ester
inchi=1/c30h40o7/c1-7-8-9-10-11-12-24(33)36-27-18(3)29(35)22-13-17(2)25(34)21(22)14-20(16-31)15-23(29)26-28(5,6)30(26,27)37-19(4)32/h9-13,15,18,21-23,26-27,31,35h,7-8,14,16h2,1-6h3/b10-9+,12-11-/t18-,21-,22-,23+,26-,27-,29+,30-/m1/s
2,4-octadienoic acid, (1ar,1bs,4ar,7ar,7br,8r,9r,9as)-9a-(acetyloxy)-1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-7b-hydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1h-cyclopropa[3,4]benz[1,2-e]azulen-9-yl
(1ar,1bs,4ar,7ar,7br,8r,9r,9as)-9a-(acetyloxy)-7b-hydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-1h-cyclopropa[3,4]benzo[1,2-e]azulen-9-yl rel-(2z,4e)-octa-2,4
pedilstatin
CHEMBL519593
LMPR0104330004
Q27105346
[(1r,2r,6r,10s,11r,13s,14r,15r)-13-acetyloxy-1-hydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-14-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] (2z,4e)-octa-2,4-dienoate

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
phorbol esterEsters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.
acetate esterAny carboxylic ester where the carboxylic acid component is acetic acid.
primary allylic alcoholAn allylic alcohol in which the carbon atom that links the double bond to the hydroxy group is also attached to two hydrogens.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID335900Cytotoxicity against mouse P388 cells2002Journal of natural products, Sep, Volume: 65, Issue:9
Isolation and structure of pedilstatin from a republic of maldives Pedilanthus sp.
AID335898Cytotoxicity against human CEM-SS cells assessed as inhibition of cell metabolic activity after 7 days by XTT assay2002Journal of natural products, Sep, Volume: 65, Issue:9
Isolation and structure of pedilstatin from a republic of maldives Pedilanthus sp.
AID335897Inhibition of [20-3H]phorbol 12,13-dibutyrate binding to protein kinase C2002Journal of natural products, Sep, Volume: 65, Issue:9
Isolation and structure of pedilstatin from a republic of maldives Pedilanthus sp.
AID335896Antiviral activity against HIV1 RF in human CEM-SS cells assessed as cell protection from infection at 2 to 5 uM after 7 days relative to control2002Journal of natural products, Sep, Volume: 65, Issue:9
Isolation and structure of pedilstatin from a republic of maldives Pedilanthus sp.
AID335899Antiviral activity against HIV1 RF in human CEM-SS cells assessed as cell protection from infection after 7 days2002Journal of natural products, Sep, Volume: 65, Issue:9
Isolation and structure of pedilstatin from a republic of maldives Pedilanthus sp.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.26 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]